Ananym Capital Management LP Takes Position in Sotera Health (NASDAQ:SHC)

Ananym Capital Management LP bought a new position in shares of Sotera Health (NASDAQ:SHC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,000,000 shares of the company's stock, valued at approximately $13,680,000. Sotera Health comprises 7.5% of Ananym Capital Management LP's investment portfolio, making the stock its 7th largest position. Ananym Capital Management LP owned 0.35% of Sotera Health at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Xponance Inc. boosted its holdings in Sotera Health by 6.0% in the fourth quarter. Xponance Inc. now owns 17,495 shares of the company's stock valued at $239,000 after acquiring an additional 989 shares during the last quarter. Blue Trust Inc. boosted its holdings in Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after acquiring an additional 1,140 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock valued at $82,000 after acquiring an additional 1,640 shares during the last quarter. Bank of Montreal Can boosted its holdings in Sotera Health by 10.6% in the fourth quarter. Bank of Montreal Can now owns 18,184 shares of the company's stock valued at $249,000 after acquiring an additional 1,740 shares during the last quarter. Finally, Quarry LP bought a new position in Sotera Health in the fourth quarter valued at about $28,000. Institutional investors own 91.03% of the company's stock.

Sotera Health Trading Up 2.2%

SHC traded up $0.27 during midday trading on Tuesday, reaching $12.43. 613,508 shares of the company were exchanged, compared to its average volume of 1,203,156. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The stock has a market capitalization of $3.53 billion, a P/E ratio of 49.72 and a beta of 1.88. The stock's 50-day simple moving average is $11.66 and its 200 day simple moving average is $12.68.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm had revenue of $254.52 million for the quarter, compared to analysts' expectations of $245.56 million. During the same quarter last year, the business earned $0.13 earnings per share. The company's revenue was up 2.6% compared to the same quarter last year. As a group, analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SHC. Barclays decreased their price target on Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Piper Sandler decreased their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and raised their price target for the company from $14.00 to $17.00 in a report on Monday, May 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.80.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.